Technical Update on Health Care Sector: Solta Medical, Orexigen Therapeutics, Vertex Pharmaceuticals, and Alere
LONDON, January 16, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Wednesday, January 15, 2014, the US equity market posted gains. The S&P 500 closed the day 0.52% higher at 1,848.38; the Dow Jones Industrial Average finished 0.66% higher at 16,481.94; and the NASDAQ Composite ended 0.76% higher at 4,214.88. The S&P 500 Health Care Sector Index ended the day at 659.40, down 0.14%; while the same has gained 6.17% in the last one month and 11.06% in the previous three months, outperforming the S&P 500, which has advanced 4.12% and 8.85% during the respective periods. The major movers in the Health Care sector included Solta Medical Inc. (NASDAQ: SLTM), Orexigen Therapeutics Inc. (NASDAQ: OREX), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Alere Inc. (NYSE: ALR). All these companies are tracked by AAAResearchReports.com. Download free technical analysis and charting reports on SLTM, OREX, VRTX, and ALR now at:
Solta Medical Inc.'s stock ended flat on Wednesday at the previous day's closing price of $2.92. The company's shares fluctuated between $2.91 and $2.92 during the trading session. A total of 2.14 million shares were traded, which is above the daily average volume of 1.40 million. The company's shares have surged 39.71% in the last one month and 40.38% in the previous three months, outperforming the S&P 500, which has advanced 4.12% and 8.85% during the respective periods. Moreover, Solta Medical Inc.'s stock is trading near its 52-week high of $2.99, and also above its 50-day and 200-day moving averages of $2.37 and $2.22, respectively. Download free research on SLTM today by registering at:
On Wednesday's, shares in Orexigen Therapeutics Inc. surged to end the day at $6.76, which is 3.36% higher than the previous day's closing price of $6.54. The company's shares vacillated between $6.43 and $6.81 during the trading session. A total of 2.50 million shares were traded, which is above the daily average volume of 2.28 million. The company's shares have gained 6.29% in the previous three trading sessions and 21.15% in the last one month, outperforming the S&P 500, which has advanced 0.33% and 4.12% during the respective periods. Additionally, Orexigen Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages of $5.67 and $6.17, respectively. Sign up and have access to our free report on OREX at:
Shares in Vertex Pharmaceuticals Inc. ended the day 0.77% lower at $78.77 on Wednesday, even as the broader market ended on a higher note. The company's shares traded between $78.20 and $79.22. A total of 1.22 million shares were traded, which is below the daily average volume of 1.84 million. Despite Wednesday's pullback, the company's shares have gained 20.85% in the last one month and 7.39% in the previous three months, compared to a gain of 4.12% and 8.85% in the S&P 500 during the respective periods. Additionally, Vertex Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $68.35 and $74.46, respectively. Sign up and read the complimentary report on VRTX at:
On Wednesday, Alere Inc.'s stock finished the day at $39.13, down 0.53% from the previous day's closing price of $39.34. The company's shares fluctuated between $39.01 and $39.50 during the trading session. A total of 0.36 million shares were traded, which is below the daily average volume of 0.54 million. Despite Wednesday's losses, the company's shares have surged 14.28% in the last one month and 26.31% in the previous three months, outperforming the S&P 500, which has advanced 4.12% and 8.85% during respective periods. Moreover, Alere Inc.'s stock is trading near its 52-week high of $39.90, and also above its 50-day and 200-day moving averages of $34.66 and $30.20, respectively. The free report on ALR can be downloaded by signing up now at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports